Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy Phillips

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Managed Care & Specialty Pharmacy|August 8, 2022
The economic burden of HIV-associated wasting in the era of modern antiretroviral therapyJaveed Siddiqui, Shanti K Samuel, Brooke Hayward, et al.
Urban Forestry & Urban Greening|June 20, 2022
The impact of the COVID-19 pandemic on the use of and attitudes towards urban forests and green spaces: Exploring the instigators of change in BelgiumNicola da Schio, Amy Phillips, Koos Fransen, et al.
Diabetes|March 9, 2016
Proinsulin Expression Shapes the TCR Repertoire but Fails to Control the Development of Low-Avidity Insulin-Reactive CD8+ T CellsJames A Pearson, Terri C Thayer, James E McLaren, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaMeletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, et al.
The Lancet. Haematology|November 5, 2025
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Meral Beksac, Ludek Pour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Blood Advances|August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsMaria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Managed Care & Specialty Pharmacy|August 8, 2022
The economic burden of HIV-associated wasting in the era of modern antiretroviral therapyJaveed Siddiqui, Shanti K Samuel, Brooke Hayward, et al.
Urban Forestry & Urban Greening|June 20, 2022
The impact of the COVID-19 pandemic on the use of and attitudes towards urban forests and green spaces: Exploring the instigators of change in BelgiumNicola da Schio, Amy Phillips, Koos Fransen, et al.
Diabetes|March 9, 2016
Proinsulin Expression Shapes the TCR Repertoire but Fails to Control the Development of Low-Avidity Insulin-Reactive CD8+ T CellsJames A Pearson, Terri C Thayer, James E McLaren, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaMeletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, et al.
The Lancet. Haematology|November 5, 2025
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Meral Beksac, Ludek Pour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Blood Advances|August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsMaria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
Pageof 2